Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Locoregionally Advanced NPC
NCT04447612Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in nasopharyngeal carcinoma (NPC) comparing Durvalumab arm with Standard of care arm (2 arms). Primary endpoint: Progression-free survival at 36 months. Status: unknown.
02
Drugs
durvalumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04447612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447612.